STAAR Surgical to Participate in Canaccord Genuity 44th Annual Growth Conference
STAAR Surgical Company (NASDAQ: STAA), a leading developer of the EVO family of Implantable Collamer® Lenses, announces its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. Patrick F. Williams, Chief Financial Officer, will engage in a fireside chat on August 13, 2024, at 8:30 a.m. Eastern Time. Investors and the public can access a live webcast of the event through STAAR's investor website.
STAAR Surgical, with over 40 years of focus on ophthalmic surgery, specializes in implantable lenses for visual freedom. Their EVO ICL™ product line has sold more than 3,000,000 ICLs globally, marketed in over 75 countries. The company operates facilities in California and Switzerland, continuing its commitment to innovative eye care solutions.
STAAR Surgical Company (NASDAQ: STAA), un sviluppatore leader della famiglia di lenti impiantabili Collamer® EVO, annuncia la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity a Boston. Patrick F. Williams, Chief Financial Officer, parteciperà a una chiacchierata informale il 13 agosto 2024, alle 8:30 ora orientale. Gli investitori e il pubblico possono accedere a una diretta web dell'evento attraverso il sito web per investitori di STAAR.
STAAR Surgical, con oltre 40 anni di esperienza nella chirurgia oftalmica, si specializza in lenti impiantabili per la libertà visiva. La loro linea di prodotti EVO ICL™ ha venduto oltre 3.000.000 di ICL a livello globale, commercializzati in oltre 75 paesi. L'azienda opera strutture in California e Svizzera, continuando il suo impegno per soluzioni innovative di cura degli occhi.
STAAR Surgical Company (NASDAQ: STAA), un desarrollador líder de la familia de lentes implantables Collamer® EVO, anuncia su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity en Boston. Patrick F. Williams, Director Financiero, participará en una charla informal el 13 de agosto de 2024, a las 8:30 a.m. hora del Este. Los inversores y el público pueden acceder a una transmisión en vivo del evento a través del sitio web para inversores de STAAR.
STAAR Surgical, con más de 40 años de enfoque en la cirugía oftálmica, se especializa en lentes implantables para la libertad visual. Su línea de productos EVO ICL™ ha vendido más de 3.000.000 de ICL a nivel mundial, comercializados en más de 75 países. La empresa opera instalaciones en California y Suiza, continuando su compromiso con soluciones innovadoras de cuidado ocular.
STAAR Surgical Company (NASDAQ: STAA), 임플란터블 콜라머® EVO 렌즈의 가족에 대한 선도적인 개발자로서, 보스턴에서 열리는 캐너코드 제뉴이티 제44회 연례 성장 회의에 참여한다고 발표했습니다. 패트릭 F. 윌리엄스, 최고 재무 책임자는 2024년 8월 13일 오전 8시 30분 동부 표준시에 대화형 세션에 참여할 것입니다. 투자자와 대중은 STAAR의 투자자 웹사이트를 통해 행사의 실시간 웹 캐스트에 접속할 수 있습니다.
STAAR Surgical은 40년 이상의 동안 안과 수술에 집중하며, 시각의 자유를 위한 임플란트 렌즈를 전문으로 합니다. 그들의 EVO ICL™ 제품군은 전 세계적으로 3,000,000개 이상의 ICL을 판매하였으며, 75개 이상의 국가에서 마케팅되고 있습니다. 이 회사는 캘리포니아와 스위스에 시설을 운영하며, 혁신적인 눈 치료 솔루션에 대한 헌신을 지속하고 있습니다.
La STAAR Surgical Company (NASDAQ: STAA), un développeur de premier plan de la famille de lentilles implantables Collamer® EVO, annonce sa participation à la 44ème Conférence Annuelle sur la Croissance de Canaccord Genuity à Boston. Patrick F. Williams, Directeur Financier, participera à une discussion informelle le 13 août 2024, à 8h30 heure de l'Est. Les investisseurs et le public peuvent accéder à un webcast en direct de l'événement via le site web des investisseurs de STAAR.
STAAR Surgical, avec plus de 40 ans d'expérience dans la chirurgie ophtalmique, se spécialise dans les lentilles implantables pour la liberté visuelle. Leur gamme de produits EVO ICL™ a vendu plus de 3.000.000 d'ICL dans le monde entier, commercialisée dans plus de 75 pays. L'entreprise possède des installations en Californie et en Suisse, poursuivant son engagement envers des solutions innovantes en matière de soins oculaires.
STAAR Surgical Company (NASDAQ: STAA), ein führender Entwickler der Familie der implantierbaren Collamer®-Linsen EVO, gibt seine Teilnahme an der 44. jährlichen Wachstumskonferenz von Canaccord Genuity in Boston bekannt. Patrick F. Williams, Chief Financial Officer, wird am 13. August 2024 um 8:30 Uhr Eastern Time an einer informellen Gesprächsrunde teilnehmen. Investoren und die Öffentlichkeit können über die Investorenseite von STAAR auf einen Live-Stream der Veranstaltung zugreifen.
STAAR Surgical, mit über 40 Jahren Erfahrung in der augenärztlichen Chirurgie, spezialisiert sich auf implantierbare Linsen für visuelle Freiheit. Ihre EVO ICL™-Produktlinie hat weltweit mehr als 3.000.000 ICLs verkauft und wird in über 75 Ländern vermarktet. Das Unternehmen betreibt Einrichtungen in Kalifornien und der Schweiz und setzt sein Engagement für innovative Lösungen im Bereich der Augenpflege fort.
- None.
- None.
Patrick F. Williams, Chief Financial Officer, will participate in a fireside chat on Tuesday, August 13, 2024, at 8:30 a.m. Eastern Time. A live webcast, including an option to pre-register, can be accessed at https://investors.staar.com/ or directly here. An archive of the webcast will also be available on STAAR’s investor website following the conference.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730909191/en/
Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com
Source: STAAR Surgical Company
FAQ
When is STAAR Surgical (STAA) participating in the Canaccord Genuity Growth Conference?
Who will represent STAAR Surgical (STAA) at the Canaccord Genuity conference?
How many ICLs has STAAR Surgical (STAA) sold to date?
In how many countries does STAAR Surgical (STAA) market its ICL products?
What is the main product line of STAAR Surgical (STAA)?
